Imipramine and amitriptyline ameliorate the rotenone model of Parkinson’s disease in rats

Highlights • Imipramine and amitriptyline abate neurodegeneration in Parkinson’s disease. • Modulation of monoamines and neurotrophin levels contributes to the neuroprotection. • Antioxidant and anti-inflammatory properties underlie the drugs’ protective effects.

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Neuroscience 2016-09, Vol.332, p.26-37
Hauptverfasser:	Kandil, Esraa A, Abdelkader, Noha F, El-Sayeh, Bahia M, Saleh, Samira
Format:	Artikel
Sprache:	eng
Schlagworte:	amitriptyline Amitriptyline - pharmacology Animals Anti-Inflammatory Agents, Non-Steroidal - pharmacology Antioxidants - pharmacology Antiparkinson Agents - pharmacology Dopaminergic Neurons - drug effects Dopaminergic Neurons - metabolism Dopaminergic Neurons - pathology imipramine Imipramine - pharmacology Immunohistochemistry Male Microglia - drug effects Microglia - metabolism Microglia - pathology Neurology neuroprotection Neuroprotective Agents - pharmacology Oxidative Stress - drug effects Oxidative Stress - physiology Parkinsonian Disorders - drug therapy Parkinsonian Disorders - pathology Parkinsonian Disorders - physiopathology Parkinson’s disease Rats, Wistar Rotarod Performance Test Rotenone Substantia Nigra - drug effects Substantia Nigra - metabolism Substantia Nigra - pathology
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Highlights • Imipramine and amitriptyline abate neurodegeneration in Parkinson’s disease. • Modulation of monoamines and neurotrophin levels contributes to the neuroprotection. • Antioxidant and anti-inflammatory properties underlie the drugs’ protective effects.
ISSN:	0306-4522 1873-7544
DOI:	10.1016/j.neuroscience.2016.06.040